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Hospital readmissions following severe infections are a major economic burden on the health care 
system and have a negative influence on patients’ quality of life. Understanding the risk factors for 
readmission, particularly the extent to which they could be prevented, is of a great importance. In this 
study we evaluated potentially preventable risk factors for 60‑day readmission in patients surviving 
hospitalization for complicated urinary tract infection (cUTI). This was a multinational, multicentre 
retrospective cohort study conducted in Europe and the Middle East. Our cohort included survivors of 
hospitalization due to cUTI during the years 2013–2014. The primary outcome was 60‑day readmission 
following index hospitalization. Patient characteristics that could have influenced readmission: 
demographics, infection presentation and management, microbiological and clinical data; were 
collected via computerized medical records from infection onset up to 60 days after hospital 
discharge. Overall, 742 patients were included. The cohort median age was 68 years (interquartile 
range, (IQR) 55–80) and 43.3% (321/742) of patients were males. The all‑cause 60‑day readmission rate 
was 20.1% (149/742) and more than half were readmitted for infection [57.1%, (80/140)]. Recurrent 
cUTI was the most frequent cause for readmission [46.4% (65/140)]. Statistically significant risk factors 
associated with 60‑day readmission in multivariable analysis were: older age (odds ratio (OR) 1.02 
for an one‑year increment, confidence interval (CI) 1.005–1.03), diabetes mellitus (OR 1.63, 95% CI 
1.04–2.55), cancer (OR 1.7, 95% CI 1.05–2.77), previous urinary tract infection (UTI) in the last year (OR 
1.8, 95% CI: 1.14–2.83), insertion of an indwelling bladder catheter (OR 1.62, 95% CI 1.07–2.45) and 
insertion of percutaneous nephrostomy (OR 3.68, 95% CI 1.67–8.13). In conclusion, patients surviving 
hospitalization for cUTI are frequently re‑hospitalized, mostly for recurrent urinary infections 
associated with a medical condition that necessitated urinary interventions. Interventions to avoid 
re‑admissions should target these patients.
Patients surviving hospitalization are frequently readmitted. About 20% of patients are re-hospitalized during 
the first month after discharge. These readmissions have a vast implication by negatively influencing the patients’ 
quality of life and imposing a significant economic burden on the health care system 1.
Severe sepsis survivors are particularly prone to readmission, and up to 50% are readmitted within 6 months 
of discharge 2. Global initiatives focusing on early diagnosis and proper management to improve the survival 
of patients hospitalized with severe sepsis, had led to a decrease of in-hospital mortality rates. As a result, the 
focus has shifted to understanding the survivors’ rehabilitation process and reducing preventable readmissions 
3–5. Recent studies addressing this issue have demonstrated that a prolonged length of hospital stay during the 
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index hospitalization was associated with higher rates of readmission. Also, patients discharged to care facilities 
had a higher risk for readmission compared to patients who were discharged home 2,6,7.
Complicated urinary tract infection is a common nosocomial infection that is responsible for a major share 
of hospital admissions, and account for 20% to 40% of severe sepsis cases 8,9. These infections are associated with 
catheterization and anatomical or functional modification of the urinary tract and thus a subject to frequent 
re-hospitalizations 10. Understanding the avoidable risk factors for readmission may inform policy for optimal 
care during hospitalization and proper post-discharge ambulatory care.
Therefore, we aimed to determine potentially preventable risk factors for readmission in patients surviving 
hospitalization following complicated urinary tract infection.
Methods
Study design, setting, and participants. This was a multinational, multicenter, retrospective cohort 
study that involved collection of data on hospitalized patients, diagnosed with complicated urinary tract infec-
tion (cUTI) as a primary cause of hospitalization or developed cUTI throughout hospitalization between 1st 
January 2013 to 31st December 2014. The study was carried out in 20 centers (8 countries) around Europe and 
the Middle East (eTable1). Patients were identified by systematic screening via hospital administration system 11 
for CD-9 CM or ICD-10 CM Codes at discharge 12,13. Eligible patients were reviewed for inclusion at each site.
This cohort was previously described in a paper by Elikaim-Raz and et al. 14.
Inclusion criteria were according to adapted Food and Drug Administration (FDA) guidance, European 
medicine agency (EMA) and clinical practice guidelines on definition of cUTI’s: Adult patients with UTI and 
at least one of the following: neurogenic bladder, indwelling urinary catheter, renal transplantation, pyelone-
phritis with normal urinary tract anatomy, obstructive uropathy, renal impairment caused by intrinsic renal 
disease, urinary retention or urinary tract modifications; and at least one of the following signs or symptoms: 
dysuria, urinary frequency, or urinary urgency, UTI-related altered mental state, chills or rigors associated with 
fever or hypothermia, costo-vertebral angle tenderness on physical examination, flank pain or pelvic pain and 
bacteriuria of  105 CFU/mL or greater of no more than 2 pathogens in urine culture or a positive blood culture 
growing possible uropathogens (of maximum 2 pathogens) without an alternative site of infection. In the present 
analysis we included patients that did not acquire their infection in the hospital, and patients that their index 
hospitalization did not result in death.
Exclusion criteria included: prostatitis, polymicrobial infections including Candida spp., polymicrobial infec-
tions of more than 2 pathogens and cUTI with Candida spp. as the only growth.
Definitions and outcomes. Data were extracted from computerized medical records and hospital admin-
istration system into a web-based electronic case report form (eCRF). Automatic validation programs, monitor-
ing, and audit were conducted by a designated third party.
Data were collected from infection onset up to 60 days after hospital discharge: demographics, patient char-
acteristics, comorbidities, Charlson comorbidity index 15, characteristics and presentation of infection, micro-
biological and clinical data, clinical management of infection including empirical antibiotic treatment, outcomes 
and details on readmission including reason for readmission and length of hospital stay. Cancer was defined 
as one of the following: leukemia, lymphoma, solid tumor or metastatic disease. Pyelonephritis was defined as 
a urinary tract infection with normal urinary tract anatomy, in the presence of fever, and involvement of the 
kidney as evidenced by flank pain or tenderness or findings on imaging.
Our primary outcome was readmission to the hospital during 60 days following index hospitalization.
Ethics statements. The study was approved by the institutional review board at Rabin Medical Center, 
Compus Beilinson and at each participating site in accordance with local regulatory requirements. Data were 
retrieved and handled anonymously in accordance with the local data protection regulation and European 
Directive on the Privacy of Data (EU (95/46/EC) 16. Also, all methods were carried out in accordance with rel-
evant guidelines and regulations. The committees waived the need for informed consent.
Statistical analysis. IBM SPSS statistics 25 software was used for statistical analysis. P values are two-tailed 
and P < 0.05 was considered statistically significant.
For the univariate analysis the following tests were used: for categorical variables- Chi-square test or Fisher’s 
exact test as appropriate, for continuous variables—Mann–Whitney test or student’s t test if normally distributed.
Statistically significant variables were tested for multicollinearity by a correlation matrix and variance infla-
tion factor (VIF) to determine the degree of correlation.
To identify independent risk factors for hospital readmission multivariable analysis using generalized esti-
mating equation (GEE) binary logistics (to account for study site as a random effect variable) was performed. 
Statistically significant variables found in univariate analysis, not strongly correlated and clinically relevant 
where introduced in this model. The Quasi-likelihood under the independence model criterion (QIC) helped 
to adjust the best model.
Prior presentations. Due to COVID-19 the presentation of this article at the 30th ECCMID (European 
Congress of Clinical Microbiology and Infectious Disease was cancelled. 
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Results
Patient characteristics. We analyzed 742 patients. Demographics, patient characteristics, infection pres-
entation and management of the index hospitalization are presented in Tables 1, 2 and 3. Among the study 
cohort, 43.3% (321/742) of patients were males and the median age was 68 years (IQR 55–80). Approximately 
30% of patients had recurrent UTI infections during the last year. Fourteen percent resided in long term care 
Table 1.  Patient characteristics for 60-day readmission. Abbreviations: UTI, urinary tract infection; LTCF, 
long term care Facility;
Entire cohort N = 742
60-day readmission (yes) 
N = 149
60-day readmission (no) 
N = 593 P value
Gender ( male) 321 (43.3%) 85 (57%) 236 (39.8%) 0.000
Age (median, (IQR)) 68 (55–80) 73 (64.5–83) 67 (53–79) 0.000
Previous 30 day antibiotic treat-
ment 146/741 (19.7%) 40 (26.8%) 106/592 (17.9%) 0.014
Place of residence—LTCF 107 (14.4%) 32 (21.5%) 75 (12.6%) 0.006
Functional capacity-Depended/
bed ridden 105/740 (14.2%) 33 (22.1%) 72/591 (12.2%) 0.002
Previous UTI infection in the 
last year 206/741 (27.8%) 57 (38.3%) 149/592 (25.2%) 0.001
Indwelling catheter at diagnosis 219/740 (29.6%) 59 (39.6%) 160/591 (27.1%) 0.003
Urinary retention 158/741 (21.3%) 43 (28.9%) 115/592 (19.4%) 0.012
Neurogenic bladder 35/740 (4.7%) 12/148 (8.1%) 23 (3.9%) 0.03
Renal impairment 191 (25.7%) 40 (26.8%) 151 (25.5%) 0.73
Obstructive uropathy 170/740 (23%) 36 (24.2%) 134/591 (22.7%) 0.7
Urinary tract modification 93/738 (12.6%) 29 (19.5%) 64/589 (10.9%) 0.005
Immunosuppressive theraphy 76 (10.2%) 16 (10.7%) 60 (10.1%) 0.823
Corticosteroid therapy 44 (5.9%) 8 (5.4%) 36 (6.1%) 0.746
Comorbidities
Dementia 102 (13.8%) 32 (21.5%) 70 (11.8%) 0.002
Myocardial infection 50 (6.7%) 14 (9.4%) 36 (6.1%) 0.148
Heart failure 129 (17.4%) 25 (16.8%) 104 (17.5%) 0.827
Peripheral vascular disease 57 (7.7%) 15 (10.1%) 42 (7.1%) 0.221
Cerebrovascular disease 132 (17.8%) 32 (21.5%) 100 (16.9%) 0.188
Chronic pulmonary disease 97 (13.1%) 19 (12.8%) 78 (13.2%) 0.897
Ulcer disease 28 (3.8%) 5 (3.4%) 23 (3.9%) 0.765
Diabetes 191 (25.7%) 53 (35.6%) 138 (23.3%) 0.002
Chronic kidney disease 212 (28.6%) 53 (35.6%) 159 (26.8%) 0.034
Hemiplegia 61 (8.2%) 15 (10.1%) 46 (7.8%) 0.359
Liver disease 42 (5.7%) 8 (5.4%) 34 (5.7%) 0.863
Solid tumor/ homological malig-
nancies (cancer) 120 (16.2%) 39 (26.2%) 81 (13.7%) 0.000
Active chemotherapy 20 (2.7%) 9 (6%) 11 (1.9%) 0.005
Charlson score (median, (IQR)) 2 (0–4) 3 (1–5) 2 (0–4) 0.000
Table 2.  Infection presentation. Abbreviations: ESBL, Extended-spectrum beta-lactamases; ICU, intensive 
care unit.
Entire cohort N = 742
60-day readmission (yes) 
N = 149
60-day readmission (no) 
N = 593 P value
Pyelonephritis 183 (24.7%) 19 (12.8%) 164 (27.7%) 0.000
Septic shock 19/688 (2.8%) 4/135 (3%) 15/553 (2.7%) 0.879
Bacteremia on sepsis onset (the 
first 48 h) 147 (18.5%) 36 (23.4%) 111 (17.3%) 0.096
ESBL-pathogen 139 (18.7%) 35 (23.5%) 104(17.5%) 0.639
ICU admission 51 (6.9%) 14 (9.4%) 37 (6.2%) 0.173
mechanical ventilation 29 (3.9%) 8 (5.4%) 21 (3.5%) 0.303
Pseudomonas aeruginosa infec-
tion 54/738 (7.3%) 15/148 (10.1%) 39/590 (6.6%) 0.141
E.coli infection 433 (58.4%) 66 (44.3%) 367(61.9%) 0.000
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facilities (107/742) and were dependent on others for daily activities (105/742) (Table 1). Bacteremia during the 
index hospitalization was documented in 18.5% (147/742) of patients (Table 2). The median length of hospital 
stay during the index hospitalization was 7 (IQR 4.75–11) and the majority of patients (87.9%, 652/742) were 
discharged home (Table 3).
Readmission. The all-cause 60-day readmission rate was 20.1% (149/742). More than half were readmitted 
for infection [57.1%, (80/140)]. The most common cause for readmission was recurrent cUTI [46.4% (65/140)]. 
A quarter of non-infection related readmissions were for urinary tract abnormalities or instrumentation (eTa-
ble2). The readmission median length of hospital stay was 7 days (IQR 4–12). Readmission rates per participat-
ing country and center are stated in eTable3 and eTable4.
Patient‑related risk factors. Readmitted patients were significantly older compared to non-readmitted 
patients 73 years (IQR 64.5–83) vs 67 years (IQR 53–79) and were more likely to be male: 57% (85/149) vs 39.8% 
(236/593). Comorbidities such as heart failure, diabetes, chronic kidney disease and cancer were more prevalent 
among the readmitted group then the comparator group. This was also demonstrated by the Charlson comorbid-
ity score.
The same was true for functional decline, residency in long term facilities and previous UTI infection during 
the last year, all more prevalent among 60-day readmission compared to those without [Table 1]. Patients admit-
ted with indwelling urinary catheter (index hospitalization) were more likely to require hospital readmission 
41/149 (27.5%) vs 114/591 (19.3%) for non-readmission, P = 0.027. Similarly, patients with urinary retention: 
28.9% (43/149) vs 19.4% (115/592); neurogenic bladder: 8.1% (12/148) vs 3.9% (23/593); and urinary tract 
modification: 19.5% (29/149) vs 10.9% (64/589) were more prone to readmission (Table 1).
Infection‑related risk factors. Sepsis severity (septic shock, bacteremia, intensive care unit (ICU) admis-
sion and mechanical ventilation) did not differ between patients that were readmitted to those who were not. 
Patients hospitalized with pyelonephritis were less likely to be readmitted during 60 days of discharge [12.8% 
(19/149) vs 27.7% (164/593), P = 0.000] (Table 2).
Management‑related risk factors. Urological interventions such as indwelling catheter replacement 
treatment and percutaneous nephrostomy were significantly more frequent among readmitted patients com-
pared to those who were not [20.1% (30/149) vs 10.7% (63/587)] and [9.4% (14/149) vs 2.4% (14/593), respec-
tively]. Patients requiring readmission had a significantly longer length of index hospital stay [8  days (IQR 
5–13)], in comparison to patients not readmitted [7 days (IQR 4–11), P = 0.021] and they were less likely to be 
discharged home [78.5% (117/149) vs. 90.2% (535/593), P = 0.000] (Table 3). We found no difference in the dura-
tion of the antibiotic treatment during hospital stay and afterwards.
Multivariable analysis. Multivariable analysis revealed the following risk factors as statistically associated 
with 60-day readmission: older age (OR 1.02 for a one-year increment, CI 1.005–1.03), cancer (OR 1.7, 95% CI 
1.05–2.77), diabetes mellitus (OR 1.63, 95% CI 1.04–2.55), previous UTI infection in the last year (OR 1.8, 95% 
CI: 1.14–2.83), insertion of an indwelling bladder catheter (OR 1.62, 95% CI 1.07–2.45) and insertion of percu-
taneous nephrostomy (OR 3.68, 95% CI 1.67–8.13) (Table 4).
Table 3.  Infection management. *Among patients with prescribed antibiotics at discharge.
Entire cohort N = 742 60-day readmission (yes) N = 149 60-day readmission (no) N = 593 P value
Appropriate empirical treatment 348/613 (56.8%) 72/123 (58.5%) 276/520 (56.3%) 0.658
Insertion of indwelling bladder catheter 266/735 (36.2%) 68/148 (45.9%) 198/587 (33.7%) 0.006
insertion of percutaneous nephrostomy 28 (3.8%) 14 (9.4%) 14 (2.4%) 0.000
Indwelling catheter replacement treatment 93/736(12.6%) 30 (20.1%) 63/587 (10.7%) 0.002
Renal replacement therapy 18 (2.4%) 4 (2.7%) 14 ( 2.4%) 0.818
Antibiotic adverse events 43/739 (5.8%) 13/148 (8.8%) 30/591 (5.1%) 0.085
Length of antibiotic treatment (days) (median, (IQR)) 6 (4–9) 6 (4–11) 6 (4–9) 0.117
Length of hospital stay (days) (median, (IQR)) 7 (4.75–11) 8 (5–13) 7 (4–11) 0.021
Discharge- home 652 (87.9%) 117 (78.5%) 535 (90.2%) 0.000
Antibiotic treatment prescribed at discharge 392/685 (57.2%) 79/142 (55.6%) 313/543 (57.6%) 0.667
Length of antibiotic treatment prescribed at discharge (days) (median, 
(IQR)), N = 679 4 (0–7) 4 (0–7) 5 (0–7) 0.701
*Length of antibiotic treatment prescribed at discharge (days) 
(median, (IQR)), N = 386 7 (5–10) 7 (5–10) 7 (5–10) 0.606
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Discussion
In this large multinational cohort one out of five patients hospitalized for cUTI was readmitted during the follow-
ing 60 days after discharge. Among them, in nearly 40% the reason was recurrent cUTI. We found that previous 
UTI infection in the last year prior the index hospitalization and insertion of urological devices (indwelling 
bladder catheter or percutaneous nephrostomy) as a treatment strategy for cUTI were strong predictors of 
60-day readmission. These findings suggest that anatomic abnormalities /dysfunction of the urinary tract are 
major risk factors for readmission. The rates of readmission were lower in patients with pyelonephritis. This can 
be explained by the fact that these patients are usually young females with a normal urinary tract anatomy and 
as such have a better prognosis compared to patients with other reasons for cUTI 17.
Disappointingly neither appropriate empirical antibiotic treatment nor the duration of antibiotic treatment 
had an influence on readmission. Prescott H.C et al. demonstrated that infection related readmissions compared 
to other medical conditions within 90-day discharge following sever sepsis can be partially prevented by early 
treatment and a better follow-up care 18. Quality of care during the index hospitalization is of importance for 
reducing readmissions following sever sepsis. the surviving sepsis campaign guidelines stress the need for early 
identification of infection and proper early antibiotic treatment 5.
Additional significant predictors for 60-day readmission were older age and comorbidities such as diabetes 
mellitus and cancer. Length of hospital stay and discharge to long term facilities were not statistically associated 
with readmission in the multivariable analysis.
In our study, similarly to previously published studies, the majority of readmissions are due to recurrent 
infection among sepsis survivals 6,19,20. Sun et al.19 retrospectively reviewed 444 sepsis survivals at risk for read-
mission from three acute care hospitals. The overall readmission rate was 23.4% with infection being the most 
common reason for hospital readmission. Among them, 51.4% were recurrent/unresolved infections. DeMerle 
et al.20 conducted a retrospective study on 1,588 survivals of hospitalization for sepsis to identify the extent to 
which the readmission was due to same site and pathogen. They found that among 472 patients re-hospitalized 
29.1% were for sepsis, of them 68.6% were for the same site but only one fifth were culture positive. Also, the 
most common site of infection was the urinary tract (29.2%).
Several studies were performed in order to identify risk factors for hospital readmission among sepsis sur-
vivals. Goodwin et al.2 retrospectively analyzed severe sepsis survivals from three hospitals around U.S states to 
evaluate predictors for hospital readmission. Among the 43,425 survivals, 20,907 patients were readmitted during 
180 days. Significant risk factors were age, male gender, race, insurance status, comorbidities such as malignancy, 
diabetes lung and chronic kidney disease, longer length of stay and discharge to care facilities.
To the best of our knowledge our study is the first to focus on patients with cUTI, hence the etiology of infec-
tion and predictors of readmission differ from previously published studies. Our study suggests that the presence 
of underlying disease which accompanies these patients, and especially pathologies and instrumentation of the 
urinary tract predisposes them to recurrent infections and frequent hospital admissions. Post-discharge strategies 
and follow up care to reduce readmission among these patients should be implemented and tested. Extensive 
strategies such as arranged follow-ups, providing discharge summaries for community physicians and patient 
education to reduce readmissions for other conditions have been implemented and found useful in many studies 
21,22. Although the need of our study papulation differ from previously published studies they provide evidence 
that the link between hospital caregivers and outpatient care may be effective in reducing readmissions.
Table 4.  Multivariable analysis for 60-day readmission. Risk factors for 60-day readmission, univariate and 
multivariate logistic regression analysis, goodness of fit -Quasi likelihood under independence model criteria 
(QIC) − 674.3, N = 728, constant β =  − 1.701. Age-per one-year increment; Length of hospital stay: per 1-day 
increment. *Statistically significant p < 0.05.
Risk factor
Multivariable logistic regression analysis OR 
(95% CI) Univariate analysis OR (95% CI)
Year of age 1.02 (1.005–1.03)* 1.02 (1.01–1.04)
Previous 30 day antibiotic treatment 1.37 (0.84–2.25) 1.68 (1.11–2.56)
Previous UTI infection in the last year 1.8 (1.14–2.83)* 1.84 (1.26–2.69)
Neurogenic bladder 2.15 (0.97–4.76) 2.18 (1.06–4.96)
Urinary tract modification 1.64 (0.92–2.95) 1.98 (1.22–3.21)
Dementia 1.47 (0.82–2.63) 2.04 (1.28–3.24)
Cancer 1.7 (1.05–2.77)* 2.24 (1.45–3.46)
Diabetes mellitus 1.63 (1.04–2.55)* 1.66 (1.13–2.42)
Chronic kidney disease 1.12 (0.73–1.74) 1.51 (1.03–2.21)
Pyelonephritis 0.58 (0.33–1.04) 0.38 (0.23–0.64)
Insertion of an indwelling bladder catheter 1.62 (1.07–2.45)* 1.67 (1.16–2.41)
indwelling bladder catheter–replacement therapy 1.54 (0.91–2.61) 2.1 (1.3–3.38)
Insertion of percutaneous nephrostomy 3.68 (1.67–8.13)* 4.29 (1.99–9.21)
Length of hospital stay 1.003 (0.99–1.01) 1.004 (1.001–1.01)
Discharge- home 0.63 (0.35–1.13) 0.39 (0.25–0.64)
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Our study has several limitations. First, this was an observational retrospective study, and as such a relatively 
weak design and particularly prone to selection bias. Secondly, patients’ were collected from 20 hospitals, in which 
the local management and diagnostic guidelines may differ. We tried to minimize this bias by close monitoring 
and strict adherence to the study protocol. Moreover, in the analysis, study center was added as a random variable, 
accounting for clustering by center. Third, we could not capture patients’ readmitted to hospitals with a different 
administrative system. This may underestimate the rate of readmissions and hence weaken the association. We 
did not collect data on the pathogens of the urinary tract infections that caused readmission. Our study’s strength 
lies in its large sample size, a multinational and multicenter design and the fact that it focuses on a specific group 
of patients with cUTI. These strengths encourage the use of our results for benchmarking.
Patients with complicated UTI and abnormalities or instrumentation of the urinary tract should be closely 
monitored after discharge from the hospital. Removal of catheters and drains as soon as possible in the com-
munity will probably prevent recurrent infections and re-admissions. Although we could not show a difference 
made by the duration of antibiotic treatment, further research on the need for antibiotic prophylaxis, the most 
suitable antibiotic drugs for acute episode and timing of device removal to prevent recurrences should be per-
formed in these patients. The results of this study stress the necessity to examine re-admissions separately in 
groups of patients according to their main reason for hospital stay.
Received: 11 November 2020; Accepted: 11 March 2021
References
 1. Jencks, S., Williams, M. & Coleman, E. Rehospitalizations among patients in the medicare fee-for-service program. J. Vasc. Surg. 
50(1), 234 (2009).
 2. Goodwin, A., Rice, D., Simpson, K. & Ford, D. Frequency, cost, and risk factors of readmissions among severe sepsis survivors*. 
Crit. Care Med. 43(4), 738–746 (2015).
 3. Kaukonen, K., Bailey, M., Suzuki, S., Pilcher, D. & Bellomo, R. Mortality related to severe sepsis and septic shock among critically 
ill patients in Australia and New Zealand, 2000–2012. JAMA 311(13), 1308 (2014).
 4. Gaieski, D., Edwards, J., Kallan, M. & Carr, B. Benchmarking the incidence and mortality of severe sepsis in the United States*. 
Crit. Care Med. 41(5), 1167–1174 (2013).
 5. Dellinger, R. et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock, 2012. 
Intens. Care Med. 39(2), 165–228 (2013).
 6. Gadre, S., Shah, M., Mireles-Cabodevila, E., Patel, B. & Duggal, A. Epidemiology and predictors of 30-day readmission in patients 
with sepsis. Chest 155(3), 483–490 (2019).
 7. Liu, V. et al. Hospital readmission and healthcare utilization following sepsis in community settings. J. Hosp. Med. 9(8), 502–507 
(2014).
 8. Wang, Z., Schorr, C., Hunter, K. & Dellinger, P. R. Contrasting treatments and outcomes of septic shock presentation on hospital 
floors versus emergency department. Chin. Med. J. 123(24), 3550–3553 (2010).
 9. Peake, S. et al. Australasian resuscitation of sepsis evaluation (ARISE): a multi-centre, prospective, inception cohort study. Resus-
citation 80(7), 811–818 (2009).
 10. Complicated Urinary Tract Infections: Developing Drugs for Treatment. Guidance for Industry (2015). U.S. Department of Health 
and Human Services, Food and Drug Administration Center for Drug Evaluation and Research (CDER).
 11. Shaw, E., Addy, I. & Stoddart, M. Retrospective observational study to assess the clinical management and outcomes of hospitalised 
patients with complicated urinary tract infection in countries with high prevalence of multidrug resistant Gram-negative bacteria 
(RESCUING). BMJ Open. 6(7), e011500 (2016).
 12. International Classification of Diseases ICD-9 Data. http:// icd9d ata. com/ 2015/ volum e1/ 580629/ defau lt. htm. http:// apps. who. int/ 
class ifica tions/ icd10/ browse/ 2015/ en.
 13. International Statistical Classification of diseases and related Health Problems 10th Revision. ICD-10. Version 2015.
 14. Eliakim-Raz, N. et al. Risk factors for treatment failure and mortality among hospitalised patients with complicated urinary tract 
infection: a multicentre retrospective cohort study, RESCUING Study Group. Clin. Infect. Dis. 68(1), 29–36 (2018).
 15. Charlson, M., Pompei, P., Ales, K. & MacKenzie, C. A new method of classifying prognostic comorbidity in longitudinal studies: 
Development and validation. J. Chronic Dis. 40(5), 373–383 (1987).
 16. Directive 95/46/EC of the European Parliament and of the Council of 24 October 1995 on the protection of individuals with regard 
to the processing of personal data and on the free movement of such data. Official Journal L 281, 23/11/1995 P. 0031–0050EU.
 17. Prescott, H. C., Langa, K. M. & Iwashyna, T. J. Readmission diagnoses after hospitalization for severe sepsis and other acute medical 
conditions. JAMA 313, 1055–1057 (2015).
 18. Czaja, C., Scholes, D., Hooton, T. & Stamm, W. Population-based epidemiologic analysis of acute pyelonephritis. Clin. Infect. Dis. 
45(3), 273–280 (2007).
 19. Sun, A. et al. Association between index hospitalization and hospital readmission in sepsis survivors*. Crit. Care Med. 44(3), 
478–487 (2016).
 20. DeMerle, K., Royer, S., Mikkelsen, M. & Prescott, H. Readmissions for recurrent sepsis. Crit. Care Med. 45(10), 1702–1708 (2017).
 21. Bradley, E. H. et al. Hospital strategies associated with 30-day readmission rates for patients with heart failure. Circ. Cardiovasc. 
Qual. Outcomes. 6(4), 444–450 (2013).
 22. Koehler, B. E. et al. Reduction of 30-day postdischarge hospital readmission or emergency department (ED) visit rates in high-risk 
elderly medical patients through delivery of a targeted care bundle. J. Hosp. Med. 4(4), 211–218 (2009).
Acknowledgements
This work was performed in partial fulfillment of the requirements for Ph.D. degree of Tanya Babich, Sackler 
Faculty of medicine, Tel Aviv University, Israel. We thank the COMBACTE MAGNET WP5 RESCUING Study 
Group and Study Sites for their kind contribution to this study.
Author contributions
I declare that all authors have seen and approved the manuscript, contributed significant to the work. T.B.—wrote 
the main manuscript, performed statistical analysis and prepared tables 1–4. N.E.—Supervised the writing 
7
Vol.:(0123456789)
Scientific Reports |         (2021) 11:6926  | https://doi.org/10.1038/s41598-021-86246-7
www.nature.com/scientificreports/
and data analysis. A.T.—Helped with the statistical analysis. All authors enrolled patients and reviewed the 
manuscript.
Funding
This research project receives support from the Innovative Medicines Initiative Joint Undertaking under Grant 
Agreement No. 115523 | 115620 | 115737| 777362 resources of which are composed of financial contribution 
from the European Union Seventh Framework Programme (FP7/2007–2013) and EFPIA companies in kind 
contribution. The research leading to these results was conducted as part of the COMBACTE-MAGNET con-
sortium. For further information please refer to www. COMBA CTE. com.
Competing interests 
Authors I.A., C.V., I.W., and C.V. belong to EFPIA (European Federation of Pharmaceutical Industries and 
Association) member companies in the IMI JU and costs related to their part in the research were carried by 
the respective company as in kind contribution under the IMI JU scheme. Other authors declare no potential 
conflicts.
Additional information
Supplementary Information The online version contains supplementary material available at https:// doi. org/ 
10. 1038/ s41598- 021- 86246-7.
Correspondence and requests for materials should be addressed to T.B.
Reprints and permissions information is available at www.nature.com/reprints.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access  This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the 
Creative Commons licence, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons licence and your intended use is not 
permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from 
the copyright holder. To view a copy of this licence, visit http:// creat iveco mmons. org/ licen ses/ by/4. 0/.
© The Author(s) 2021
